News
AZ aims to cut cancer clinic visits with new Imfinzi regimen
The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic visits for patients wit
